Journal of Korean Society of Health-System Pharmacists

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN    pISSN

Table. 1.

Table. 1.

Differences in clinical characteristics between the cases infected with bacteria susceptible to ceftizoxime/amikacin and infected with bacteria resistant to ceftizoxime/amikacin in hematologic disease patients with bacteremic neutropenic fever after chemotherapy

Susceptible bacterial infection (n=129) Resistant bacterial infection (n=61) P-Value
Demographics
Male sex 71 (55.0%) 31 (50.8%) 0.586
Age (years, mean±SD) 54.0±13.8 53.1±14.8 0.656
CCI score (score, mean±SD) 2.5±1.2 3.2±2.9 0.051
Baseline disease
Hematopoietic stem cell transplant 12 (9.3%) 7 (11.5%) 0.641
Acute leukemia 117 (90.7%) 54 (88.5%) 0.641
ICU care for neutropenic fever 12 (9.3%) 9 (14.7%) 0.322
Empirical antibiotic
Ceftizoxime/amikacin 60 (46.5%) 23 (37.7%) 0.253
Onset of bacteremia with shock 16 (12.4%) 10 (16.4%) 0.455
Ciprofloxacin prophylaxis 9 (6.9%) 7 (11.4%) 0.297
Steroid use 23 (17.8%) 19 (31.1%) 0.039
Immunosuppressant use 8 (6.2%) 6 (9.8%) 0.383*
Antibiotics exposure
3rd generation cephalosporin 20 (15.5%) 21 (34.4%) 0.003
Aminoglycoside 18 (13.9%) 11 (18.0%) 0.519
Piperacillin/tazobactam 20 (15.5%) 18 (29.5%) 0.024
Fluoroquinolone 28 (21.7%) 20 (32.8%) 0.101
Carbapenem 7 (5.4%) 4 (6.5%) 0.748*
Glycopeptide 10 (7.8%) 4 (6.5%) 1.000*
Other beta-lactams 9 (6.9%) 8 (13.1%) 0.166
Mortality 1 (0.8%) 5 (8.2%) 0.001

CCI; Charlson’s comorbidity index; ICU; intensive care unit

*These p-Value were calculated by Fisher’s exact test

Mortality was defined as death within the first 30 days of infection.

It is defined as the case of use or exposure within 30 days prior to onset of bacteremia.

J. Kor. Soc. Health-syst. Pharm. 2021;38:319-30 https://doi.org/10.32429/jkshp.2021.38.3.003
© 2021 J. Kor. Soc. Health-syst. Pharm.